View in EDS

Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials.

Saved in:

Bibliographic Details
Title:	Safety and Tolerability of Adjunctive Lumateperone for the Treatment of Major Depressive Disorder: A Pooled Analysis of Two Randomized Placebo-Controlled Trials.
Authors:	Earley WR; Intra-Cellular Therapies, a Johnson & Johnson Company, 135 US Highway 202/206, Suite 6, Bedminster, NJ, 07921, USA. wearley@its.jnj.com., Durgam S; Intra-Cellular Therapies, a Johnson & Johnson Company, 135 US Highway 202/206, Suite 6, Bedminster, NJ, 07921, USA., Kozauer SG; Former Employee, Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ, USA., Chen C; Intra-Cellular Therapies, a Johnson & Johnson Company, 135 US Highway 202/206, Suite 6, Bedminster, NJ, 07921, USA., Migliore R; Intra-Cellular Therapies, a Johnson & Johnson Company, 135 US Highway 202/206, Suite 6, Bedminster, NJ, 07921, USA., Correll CU; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.; German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany.
Source:	CNS drugs [CNS Drugs] 2026 Jul 15. Date of Electronic Publication: 2026 Jul 15.
Publication Type:	Journal Article
Journal Info:	Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1179-1934
DOI:	10.1007/s40263-026-01314-8